Poster 1425 Fecal Microbiota Transplantation Improves Microbiome Diversity and Liver Enzyme Profile in Primary Sclerosing Cholangitis

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

    *EMBARGOED All research presented at the World Congress of Gastroenterology at ACG2017 is strictly embargoed until Monday, October 16, 2017, at 8:00 am EDT.


    Jessica R. Allegretti, MD, MPH

    Poster 1425 Fecal Microbiota Transplantation Improves Microbiome Diversity and Liver Enzyme Profile in Primary Sclerosing Cholangitis

    Author Insight from Jessica R. Allegretti, MD, MPH, Brigham & Women’s Hospital

    What’s new here and important for clinicians?

    To our knowledge, this is the first study to demonstrate that fecal microbiota transplantation from a rationally selected donor is safe, increases microbial diversity, and may improve alkaline phosphatase among Primary Sclerosing Cholangitis (PSC) patients. This is crucial given this is a disease that to date has no FDA-approved therapies.

    What do patients need to know?

    This is the first study to explore the use of fecal transplantation for the treatment of PSC. This will help us to better understand what role the gut microbiome plays in the disease and to develop more-effective therapies for this disease.

    Read the Abstract

    Author Contact
    Jessica R. Allegretti, MD, MPH, Brigham & Women’s Hospital
    jallegretti@partners.org


    Media Interview Requests:

    To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at mediaonly@gi.org or by phone at 301-263-9000.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks